{"protocolSection": {"identificationModule": {"nctId": "NCT02126839", "orgStudyIdInfo": {"id": "ABS-AS-303"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics", "officialTitle": "A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-05"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-04-28", "studyFirstSubmitQcDate": "2014-04-28", "studyFirstPostDateStruct": {"date": "2014-04-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-01-06", "resultsFirstSubmitQcDate": "2016-01-06", "resultsFirstPostDateStruct": {"date": "2016-02-05", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2015-07-13", "dispFirstSubmitQcDate": "2015-07-13", "dispFirstPostDateStruct": {"date": "2015-08-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-11-05", "lastUpdatePostDateStruct": {"date": "2021-11-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study is to evaluate the chronic-dose efficacy and the safety of Albuterol MDPI compared to placebo in pediatric participants with asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 186, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo MDPI QID", "type": "PLACEBO_COMPARATOR", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.", "interventionNames": ["Drug: Placebo", "Drug: ProAir HFA inhaler"]}, {"label": "Albuterol MDPI 180 mcg QID", "type": "EXPERIMENTAL", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.", "interventionNames": ["Drug: Albuterol MDPI", "Drug: ProAir HFA inhaler"]}], "interventions": [{"type": "DRUG", "name": "Albuterol MDPI", "description": "90 mcg/actuation of the multidose dry powder inhaler (MDPI).", "armGroupLabels": ["Albuterol MDPI 180 mcg QID"], "otherNames": ["Spiromax\u00ae"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching Placebo delivered via a multidose dry powder inhaler (MDPI).", "armGroupLabels": ["Placebo MDPI QID"]}, {"type": "DRUG", "name": "ProAir HFA inhaler", "description": "Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.", "armGroupLabels": ["Albuterol MDPI 180 mcg QID", "Placebo MDPI QID"], "otherNames": ["albuterol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks", "description": "Following measurement of the baseline FEV1 and dose administration on Days 1 and 22, FEV1 values (highest of 3 acceptable maneuvers) will be obtained at 5 (\u00b12), 15 (\u00b15), 30 (\u00b15), 45 (\u00b15), 60 (\u00b110), 120 (\u00b110), 240 (\u00b110), and 360 (\u00b110) minutes after the completion of dosing. Predicted FEV1 values were computed and adjusted for age, height, and gender according to Eigen et al (Eigen et al 2001) for participants 4 to 5 years of age and to Quanjer et al (Quanjer et al 1995) for participants aged 6 to 11 years using ATS criteria (American Thoracic Society/European Respiratory Society Statement 2007).", "timeFrame": "30 \u00b15 and 5 \u00b12 minutes prior to dosing, and at 5 \u00b12, 15 \u00b15, 30 \u00b15, 45 \u00b15, 60 \u00b110, 120 \u00b110, 240 \u00b110, and 360 \u00b110 minutes after completion of dosing on Days 1 and 22"}], "secondaryOutcomes": [{"measure": "Baseline Adjusted Peak Expiratory Flow (PEF) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks", "description": "Serial PEF measurements were obtained via spirometry. PEF measures for purpose of serial PEF assessment (pre and postdose) were collected from the spirometer assessed PEF, utilizing the values from the efforts selected based on the highest of 3 acceptable FEV1 maneuvers.", "timeFrame": "30 \u00b15 and 5 \u00b12 minutes prior to dosing, and at 5 \u00b12, 15 \u00b15, 30 \u00b15, 45 \u00b15, 60 \u00b110, 120 \u00b110, 240 \u00b110, and 360 \u00b110 minutes after completion of dosing on Days 1 and 22"}, {"measure": "Summary of Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).\n\nRelation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "6 Months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Written informed consent/assent signed and dated by the patient and/or parent/caregiver/legal guardian (as appropriate) before conducting any study related procedure\n2. Male or premenarchal female 4-11 years of age, inclusive, as of the screening visit (SV)\n3. Has a documented physician diagnosis of asthma per the EPR-3 Guidelines of a minimum of 6 months duration that has been stable for at least 4 weeks prior to the SV\n4. Has the ability to perform spirometry reproducibly consistent with ATS guidelines and protocol-specific guidelines\n5. Has FEV1 50-95% predicted for age, height and gender at the SV following a minimum 6-hour period without \u03b22-agonist use. (Note: Predicted values of 49.50-49.99% may be rounded up to 50% and values of 95.01-95.49% may be rounded down to 95%.)\n6. Demonstrated reversible bronchoconstriction as verified by a 15% or greater increase in baseline FEV1 within 30 minutes following inhalation of 180 mcg of albuterol. (Note: Reversibility values of 14.50-14.99% may be rounded up to 15%.)\n7. Is maintained on low-dose inhaled corticosteroids (ICS, less than or equal to 200 mcg of fluticasone propionate per day or equivalent), leukotriene modifiers (LTM), or inhaled cromones, and/or on short-acting \u03b22-agonists (SABA); as needed SABA alone is acceptable. The ICS, LTM, and cromone doses must have been stable for at least 4 weeks prior to the SV and should be maintained for the duration of the study\n8. Can self-perform peak expiratory flow rate (PEF) measurements with a handheld peak flow meter\n9. Can tolerate the withdrawal of applicable medications for qualification at screening\n10. Otherwise in general good health, defined as free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the trial, and with a clinically acceptable 6-month medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs\n11. Parents consenting are capable of understanding the requirements, risks and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and being compliant with all study requirements (eg, visits, record-keeping)\n12. The patient is able to correctly use the MDPI device, either alone or with assistance by a parent/guardian.\n\nExclusion Criteria\n\n1. Known hypersensitivity to albuterol or any of the excipients in the inhaler formulations (eg, lactose, ethanol)\n2. Participation (receiving study medication) in any investigational drug trial within the 30 days preceding the SV or planned participation in another investigational drug trial at any time during this trial\n3. History of severe milk protein allergy\n4. History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza) that has not resolved within 4 weeks preceding the SV\n5. Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A patient must not have had any hospitalization for asthma within 6 months prior to the SV.\n6. Initiation of immunotherapy during the study period or dose escalation during the study period. Patients being treated with immunotherapy prior to the SV must be using a stable (maintenance) dose (90 days or more) to be considered for inclusion.\n7. History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures\n8. Use of any prohibited concomitant medications within the washout prescribed per protocol prior to study visits\n9. Use of any medication for asthma or allergic rhinitis that is prohibited per the protocol as described in the protocol\n10. The dosage of any required LTM, ICS, or inhaled cromones, has not been stable for at least 4 weeks. Intranasal corticosteroid and/or cromones have not been stable for at least two weeks prior to the SV. Allowed corticosteroid, LTM, and cromone asthma and allergy medications should be continued at the same doses during the conduct of the study.\n11. Presence of any non-asthmatic acute or chronic condition, including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis, cystic fibrosis, clinically significant cardiovascular disease (including but not limited to cardiac arrhythmias and uncontrolled hypertension), clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes mellitus, hyperthyroidism, convulsive disorder, and malignancy other than basal cell carcinoma. Significant is defined as any condition that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which could affect the safety or efficacy analyses\n12. Any other medical or psychological condition that in the investigator's opinion should preclude study enrollment\n13. Previous participation (received MDPI study medication) in an Albuterol MDPI study\n14. Study participation by clinical investigator site employees and/or their immediate relatives\n15. Study participation by related or non-related individuals living in the same household, ie, only one subject per household may participate in the study at the same time.\n16. Require continuous treatment with \u03b2-blockers, MAO inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids\n17. Treated with oral or injectable corticosteroids within the 6 weeks prior to SV\n18. Hospitalization for acute asthma exacerbation \\>2 times in 12 months prior to screening and/or received emergency room treatment other than nebulized albuterol or been hospitalized for asthma exacerbations within 6 months prior to SV", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sponsor's Medical Expert, MD", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 12496", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Teva Investigational Site 12500", "city": "Mobile", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Teva Investigational Site 12481", "city": "Little Rock", "state": "Alaska", "country": "United States"}, {"facility": "Teva Investigational Site 12515", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Teva Investigational Site 12505", "city": "Costa Mesa", "state": "California", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Teva Investigational Site 12476", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 12519", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Teva Investigational Site 12484", "city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Teva Investigational Site 12510", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Teva Investigational Site 12483", "city": "Rolling Hills Estates", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Teva Investigational Site 12511", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Teva Investigational Site 12485", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Teva Investigational Site 12512", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Teva Investigational Site 12522", "city": "Gainesville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Teva Investigational Site 12535", "city": "Hollywood", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Teva Investigational Site 12526", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 12516", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Teva Investigational Site 12517", "city": "Tamarac", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.21286, "lon": -80.24977}}, {"facility": "Teva Investigational Site 12527", "city": "Vero Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.63864, "lon": -80.39727}}, {"facility": "Teva Investigational Site 12513", "city": "Winter Park", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Teva Investigational Site 12486", "city": "Gainesville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Teva Investigational Site 12497", "city": "Lawrenceville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Teva Investigational Site 12480", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Teva Investigational Site 12508", "city": "Shiloh", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 38.56144, "lon": -89.89732}}, {"facility": "Teva Investigational Site 12518", "city": "Iowa City", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Teva Investigational Site 12523", "city": "Covington", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.47549, "lon": -90.10042}}, {"facility": "Teva Investigational Site 12495", "city": "Warrensburg", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "Teva Investigational Site 12509", "city": "Northfield", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Teva Investigational Site 12524", "city": "Brooklyn", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Teva Investigational Site 12473", "city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Teva Investigational Site 12477", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 12525", "city": "Cleveland", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Teva Investigational Site 12502", "city": "Middleburg Heights", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Teva Investigational Site 12478", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 12487", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 12506", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 12492", "city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Teva Investigational Site 12507", "city": "Gresham", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.49818, "lon": -122.43148}}, {"facility": "Teva Investigational Site 12501", "city": "Normal", "state": "Pennsylvania", "country": "United States"}, {"facility": "Teva Investigational Site 12493", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Teva Investigational Site 12488", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Teva Investigational Site 12514", "city": "Greenville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Teva Investigational Site 12474", "city": "Orangeburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "Teva Investigational Site 12479", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Teva Investigational Site 12489", "city": "Boerne", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Teva Investigational Site 12475", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Teva Investigational Site 12491", "city": "Burke", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "Teva Investigational Site 12504", "city": "Charlottesville", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}, {"facility": "Teva Investigational Site 12482", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Teva Investigational Site 12498", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Teva Investigational Site 12490", "city": "Spokane", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Teva Investigational Site 12533", "city": "Papillion", "state": "NE", "country": "Thailand"}]}, "referencesModule": {"references": [{"pmid": "27523719", "type": "DERIVED", "citation": "Ratnayake A, Taveras H, Iverson H, Shore P. Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. Allergy Asthma Proc. 2016 Sep;37(5):370-5. doi: 10.2500/aap.2016.37.3985. Epub 2016 Aug 12."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The run-in period (days -14 to Day -1) was conducted in a single blind manner with respect to the Placebo MDPI treatment (2 inhalations QID at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime), so that the patient did not know which treatment was administered.", "groups": [{"id": "FG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks."}, {"id": "FG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "Safety Population", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "93"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "92"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "80"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by parent/guardian", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Sponsor request", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized participants", "groups": [{"id": "BG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks."}, {"id": "BG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "186"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.5", "spread": "1.83"}, {"groupId": "BG001", "value": "8.3", "spread": "1.69"}, {"groupId": "BG002", "value": "8.4", "spread": "1.76"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "4-7 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "53"}]}]}, {"title": "8-11 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "133"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "79"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "107"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "81"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "100"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "161"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.2", "spread": "13.42"}, {"groupId": "BG001", "value": "36.1", "spread": "13.46"}, {"groupId": "BG002", "value": "36.7", "spread": "13.42"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "136.9", "spread": "12.67"}, {"groupId": "BG001", "value": "135.2", "spread": "11.59"}, {"groupId": "BG002", "value": "136.0", "spread": "12.13"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19.5", "spread": "4.96"}, {"groupId": "BG001", "value": "19.4", "spread": "5.34"}, {"groupId": "BG002", "value": "19.4", "spread": "5.14"}]}]}]}, {"title": "Screening FEV1", "description": "FEV1 = forced expiratory volume in 1 second", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.69", "spread": "0.44"}, {"groupId": "BG001", "value": "1.64", "spread": "0.35"}, {"groupId": "BG002", "value": "1.66", "spread": "0.39"}]}]}]}, {"title": "Screening PPFEV1", "description": "PPFEV1 = percent-predicted forced expiratory volume in 1 second", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent of predicted FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "87.5", "spread": "11.46"}, {"groupId": "BG001", "value": "89.0", "spread": "12.35"}, {"groupId": "BG002", "value": "88.3", "spread": "11.91"}]}]}]}, {"title": "Qualifying Airway Reversibility", "description": "For a patient to be eligible for study enrollment, a minimum of 15% increase from the baseline FEV1 must be demonstrated after receiving 180 mcg of albuterol, administered as 2 actuations 1 minute apart.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage increase from baseline FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22.0", "spread": "8.14"}, {"groupId": "BG001", "value": "22.9", "spread": "8.19"}, {"groupId": "BG002", "value": "22.4", "spread": "8.16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks", "description": "Following measurement of the baseline FEV1 and dose administration on Days 1 and 22, FEV1 values (highest of 3 acceptable maneuvers) will be obtained at 5 (\u00b12), 15 (\u00b15), 30 (\u00b15), 45 (\u00b15), 60 (\u00b110), 120 (\u00b110), 240 (\u00b110), and 360 (\u00b110) minutes after the completion of dosing. Predicted FEV1 values were computed and adjusted for age, height, and gender according to Eigen et al (Eigen et al 2001) for participants 4 to 5 years of age and to Quanjer et al (Quanjer et al 1995) for participants aged 6 to 11 years using ATS criteria (American Thoracic Society/European Respiratory Society Statement 2007).", "populationDescription": "The full analysis set (FAS) includes all participants in the ITT population who receive at least 1 dose of study medication and have at least 1 postbaseline assessment of the primary endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% predicted FEV1/hour", "timeFrame": "30 \u00b15 and 5 \u00b12 minutes prior to dosing, and at 5 \u00b12, 15 \u00b15, 30 \u00b15, 45 \u00b15, 60 \u00b110, 120 \u00b110, 240 \u00b110, and 360 \u00b110 minutes after completion of dosing on Days 1 and 22", "groups": [{"id": "OG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks."}, {"id": "OG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.71", "spread": "3.190"}, {"groupId": "OG001", "value": "43.73", "spread": "3.200"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "mixed model repeated measures analysis", "statisticalComment": "Fixed effects of treatment group, treatment day, and study day by treatment interaction, with baseline measured at each study day as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "25.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "16.10", "ciUpperLimit": "33.94", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.52"}]}, {"type": "SECONDARY", "title": "Baseline Adjusted Peak Expiratory Flow (PEF) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks", "description": "Serial PEF measurements were obtained via spirometry. PEF measures for purpose of serial PEF assessment (pre and postdose) were collected from the spirometer assessed PEF, utilizing the values from the efforts selected based on the highest of 3 acceptable FEV1 maneuvers.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/min*hour", "timeFrame": "30 \u00b15 and 5 \u00b12 minutes prior to dosing, and at 5 \u00b12, 15 \u00b15, 30 \u00b15, 45 \u00b15, 60 \u00b110, 120 \u00b110, 240 \u00b110, and 360 \u00b110 minutes after completion of dosing on Days 1 and 22", "groups": [{"id": "OG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks."}, {"id": "OG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71.52", "spread": "10.201"}, {"groupId": "OG001", "value": "147.85", "spread": "10.245"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "mixed model repeated measures", "statisticalComment": "Fixed effects of treatment group, treatment day, and study day by treatment interaction, with baseline measured at each study day as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "76.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "47.76", "ciUpperLimit": "104.91", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "14.47"}]}, {"type": "SECONDARY", "title": "Summary of Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).\n\nRelation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "Safety Analysis set includes all participants who receive at least 1 dose of study drug. In this population, treatment is assigned based upon the treatment participants actually receive, regardless of the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "6 Months", "groups": [{"id": "OG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks."}, {"id": "OG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Severe adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-related adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Other serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Withdrawn from study due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Day 1 to Day 22", "eventGroups": [{"id": "EG000", "title": "Placebo MDPI QID", "description": "Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 92, "otherNumAffected": 19, "otherNumAtRisk": 92}, {"id": "EG001", "title": "Albuterol MDPI 180 mcg QID", "description": "Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 93, "otherNumAffected": 9, "otherNumAtRisk": 93}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}